OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain
OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain
  • PR Newswire
  • 승인 2020.11.24 23:00
  • 댓글 0
이 기사를 공유합니다

SEOUL, South Korea, Nov. 24, 2020 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to commission a Scientific Advisory Board ("SAB") of key experts in sodium ion channelopathy and pain. The SAB will advise OliPass on the clinical development of OLP-1002, an SCN9A antisense pain killer being evaluated in moderate to severe osteoarthritis patients with pain in Phase1/b clinical trial. "We are more than thrilled to work with such a distinguished group of pioneers in the field of sodium ion channelopathy", said Dr. Shin Chung, the founder and CEO of OliPass Corporation. "There is a pressing need for more effective, non-opiate treatments for pain. Building upon impressive early progress, OliPass has now recruited world-class experts to help shape clinical studies. I look forward to progress, and hopefully to a much-needed new approach to treatment of pain", said Professor Stephen Waxman of Yale University who will chair the SAB.

Professor Waxman led a team that identified sodium ion channel Nav1.7 as a regulator of pain. He has since contributed to studies that have provided evidence that Nav1.7 blockers can reduce pain in erythromelalgia (man-on-fire syndrome) and trigeminal neuralgia. He served as chairman of neurology at Yale University and founded the neuroscience & regeneration research center. Professor David Bennett of Oxford University and Professor Catharina Faber of Maastricht University will also join the SAB. Professor Bennett's research interest is the genetics of neuropathic pain ranging from rare pain channelopathies to common acquired neuropathic pain. Professor Faber's research focuses on genetic causes of small fiber neuropathy.

People with a loss-of-function mutation of the SCN9A gene were found insensitive to pain but with other sensory functions undisturbed. Since the SCN9A gene encodes Nav1.7 sodium ion channel subtype, a selective inhibitor of Nav1.7 has been implicated to be a pain killer with strong efficacy and excellent safety. Unfortunately there are at least 10 sodium ion channels structurally almost indistinguishable with small molecule inhibitors. Although small molecule inhibitors of Nav1.7 have been abundantly evaluated, none have manifested strong analgesic efficacy and good safety most likely due to lack of Nav1.7 selectivity.

OLP-1002 is an antisense OPNA (OliPass Peptide Nucleic Acid) selectively targeting the SCN9A pre-mRNA to induce exon skipping, and inhibits the expression of Nav1.7 only. OLP-1002 reproduces much of the clinical phenotype of people with SCN9A channelopathy. Unlike small molecule Nav1.7 inhibitors with limited Nav1.7 selectivity, OLP-1002 is expected to safely treat various types of pain as a selective inhibitor of Nav1.7. Considering that there are not many safe therapeutic options available for chronic pain, neuropathic pain, cancer pain and various types of refractory pain, OLP-1002 is expected to markedly enhance quality of life by replacing popular pain killers such as NSAIDs, opioids, anti-depressants, and anti-epileptic drugs. The strong efficacy and excellent safety of OLP-1002 shall triger positive changes in the global pain killer market of currently about 100 billion USD per year.

(About OliPass Corporation)

OliPass Corporation is a public biotech company listed in KOSDAQ in South Korea (ticker: KQ244460). The company is developing RNA therapeutics based on its proprietary oligonucleotide platform called OPNA (Olipass Peptide Nucleic Acid). OPNA was derived from PNA by rational chemical modifications in order to improve the cell permeability and RNA affinity. For therapeutic intervention, OPNA potently binds to target pre-mRNA, induces exon skipping, and yields mRNA splice variant. Unlike other types of RNA therapeutics, OPNA does not require formulational aid for in vivo therapeutic activity.

(Media Contact)
OliPass Finance Director. Jaehyun Kim
jkim@olipass.com

 

info@prnasia.com

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.